What is the role of current mass spectrometry in pharmaceutical analysis?

被引:18
|
作者
Khalikova, Maria [1 ,2 ]
Jires, Jakub [3 ,4 ]
Horacek, Ondrej [5 ]
Dousa, Michal [4 ]
Kucera, Radim [5 ]
Novakova, Lucie [1 ,6 ]
机构
[1] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Analyt Chem, Hradec Kralove, Czech Republic
[2] Univ Hradec Kralove, Dept Chem, Fac Sci, Hradec Kralove, Czech Republic
[3] UCT Prague, Fac Chem Engn, Dept Analyt Chem, Prague, Czech Republic
[4] Zentiva Ks, Dept Dev, Prague, Czech Republic
[5] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Pharmaceut Chem & Pharmaceut Anal, Hradec Kralove, Czech Republic
[6] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Analyt Chem, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic
关键词
biopharmaceutical; gas chromatography; genotoxic impurity; liquid chromatography; mass spectrometry; pharmaceutical analysis; SIZE-EXCLUSION CHROMATOGRAPHY; PHASE LIQUID-CHROMATOGRAPHY; PRESSURE CHEMICAL-IONIZATION; HYDROPHILIC INTERACTION CHROMATOGRAPHY; CATION-EXCHANGE CHROMATOGRAPHY; ANTIBODY CHARGE HETEROGENEITY; BILAYER-COATED CAPILLARIES; THIN-LAYER-CHROMATOGRAPHY; UNDERIVATIZED AMINO-ACIDS; LC-MS CHARACTERIZATION;
D O I
10.1002/mas.21858
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
The role of mass spectrometry (MS) has become more important in most application domains in recent years. Pharmaceutical analysis is specific due to its stringent regulation procedures, the need for good laboratory/manufacturing practices, and a large number of routine quality control analyses to be carried out. The role of MS is, therefore, very different throughout the whole drug development cycle. While it dominates within the drug discovery and development phase, in routine quality control, the role of MS is minor and indispensable only for selected applications. Moreover, its role is very different in the case of analysis of small molecule pharmaceuticals and biopharmaceuticals. Our review explains the role of current MS in the analysis of both small-molecule chemical drugs and biopharmaceuticals. Important features of MS-based technologies being implemented, method requirements, and related challenges are discussed. The differences in analytical procedures for small molecule pharmaceuticals and biopharmaceuticals are pointed out. While a single method or a small set of methods is usually sufficient for quality control in the case of small molecule pharmaceuticals and MS is often not indispensable, a large panel of methods including extensive use of MS must be used for quality control of biopharmaceuticals. Finally, expected development and future trends are outlined.
引用
收藏
页码:560 / 609
页数:50
相关论文
共 50 条